0IJO Stock Overview
An oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States. More details
| Snowflake Score | |
|---|---|
| Valuation | 5/6 |
| Future Growth | 3/6 |
| Past Performance | 5/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Exelixis, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$35.55 |
| 52 Week High | US$36.71 |
| 52 Week Low | US$19.62 |
| Beta | 0.51 |
| 11 Month Change | 26.63% |
| 3 Month Change | 37.85% |
| 1 Year Change | 63.98% |
| 33 Year Change | 107.17% |
| 5 Year Change | 117.03% |
| Change since IPO | 17.45% |
Recent News & Updates
Recent updates
Shareholder Returns
| 0IJO | GB Biotechs | GB Market | |
|---|---|---|---|
| 7D | 2.4% | 0.3% | 2.2% |
| 1Y | 64.0% | -18.3% | 8.0% |
Return vs Industry: 0IJO exceeded the UK Biotechs industry which returned -18.3% over the past year.
Return vs Market: 0IJO exceeded the UK Market which returned 8% over the past year.
Price Volatility
| 0IJO volatility | |
|---|---|
| 0IJO Average Weekly Movement | 5.4% |
| Biotechs Industry Average Movement | 9.7% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in GB Market | 10.3% |
| 10% least volatile stocks in GB Market | 2.6% |
Stable Share Price: 0IJO has not had significant price volatility in the past 3 months compared to the UK market.
Volatility Over Time: 0IJO's weekly volatility (5%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1994 | 1,310 | Mike Morrissey | www.exelixis.com |
Exelixis, Inc., an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States. The company offers CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of progressive and metastatic medullary thyroid cancer. Its CABOMETYX and COMETRIQ are derived from cabozantinib, an inhibitor of multiple tyrosine kinases, including MET, AXL, RET, and VEGF receptors.
Exelixis, Inc. Fundamentals Summary
| 0IJO fundamental statistics | |
|---|---|
| Market cap | US$10.17b |
| Earnings (TTM) | US$466.92m |
| Revenue (TTM) | US$2.08b |
21.8x
P/E Ratio4.9x
P/S RatioIs 0IJO overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 0IJO income statement (TTM) | |
|---|---|
| Revenue | US$2.08b |
| Cost of Revenue | US$78.00m |
| Gross Profit | US$2.00b |
| Other Expenses | US$1.54b |
| Earnings | US$466.92m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 1.64 |
| Gross Margin | 96.25% |
| Net Profit Margin | 22.43% |
| Debt/Equity Ratio | 0% |
How did 0IJO perform over the long term?
See historical performance and comparison